A wobbly Biogen makes a surprise switch in the executive suite, triggering a renewed burst of M&A chatter
Right on the eve of releasing their Q2 numbers, Biogen $BIIB managed to surprise just about everyone with the news Tuesday night that CFO Jeff Capello — in the hot seat for less than 3 years — had hit the exit, with his replacement set to arrive in a couple of weeks. And speculation immediately turned to figuring out what was afoot, given the high wire act that the big biotech is currently engaged in with aducanumab.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.